Search
-
The Justin Perry Lab
… Job Title Administrative Assistant II Start Year 2017 Email [email protected]
-
With broad potential applicability, the EBP methodology can be used to develop strategies and solutions relating to a wide range of clinical inquiries. It has been heavily validated in academic-research literature—and, most significantly, in the healthcare community.
… What is Evidence-based Practice (EBP)? Evidence-based Practice (EBP) is a problem-solving methodology that helps to guide healthcare practices and decisions through the use of current and best evidence from studies, combined with patient care data, clinician expertise, and patient preferences. According
-
The Daniel Heller Lab
… Tea will be served at 3:45 p.m. , immediately preceding the seminar. Audience This seminar is open to the research community. Location Memorial Sloan Kettering Cancer Center Rockefeller Research Laboratories 430 East 67th Street Room RRL-116 New York, NY 10065 Speaker(s) Jinwoo Cheon, PhD Founding Director
-
Patient & Caregiver Education
This video will help you prepare for your new visit with Dr. Vincent Laudone about newly diagnosed prostate cancer.
… This video will help you prepare for your new visit with Dr. Vincent Laudone about newly diagnosed prostate cancer.
-
The Richard Kolesnick Lab
… Our and other laboratories have defined a new class of upstream signals necessary for normal development and/or oncogenesis via Ras. One component, Kinase Suppressor of Ras1 (KSR1), was originally identified in Drosophila melanogaster and Caenorhabditis elegans to function as a positive modulator of
-
-
-
The Cristina Antonescu Lab
… Antonescu CR , Agaram NP, Sung YS, Zhang L, Swanson D, Dickson BC. (2018). A distinct malignant epithelioid neoplasm with GLI1 gene rearrangements, frequent S100 protein expression, and metastatic potential: expanding the spectrum of pathologic entities with ACTB/MALAT1/PTCH1-GLI1 fusions . Am J Surg
-
Clinical Trial
… Full Title A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal